Progress in veterinary medicine is slow
Cancer is the leading cause of death among dogs and cats. Almost 50% of dogs and 33% of cats over the age of 10 will die of cancer. Billions in research dollars have been spent to improve our own health, yet progress in veterinary medicine lags years behind the scientific breakthroughs seen in human health. This innovation gap between human science and veterinary medicine costs the lives of millions of beloved pets and is the primary reason Animal Life Sciences was founded.
Animal Life Sciences: applying human health innovations to pets
Animal Life Sciences is a nutritional and pharmaceutical development company focused on the licensing, development and commercialization of safe and effective treatments for cats and dogs suffering from some of the most deadly diseases. We were founded by leading scientists, clinicians and executives to create health care solutions for pets based on cutting-edge human cancer technologies.
Animal Life Sciences was founded by leading scientists, clinicians and executives with decades of experience in drug discovery and bringing products to the market.
Our strategy is to leverage the breakthrough advances in human drug development generated from leading cancer research institutions, by applying them to veterinary medicine under the guidance of our leading experts.
We plan to continue to expand our development pipeline by licensing more drug technologies and to utilize our scientific and clinical expertise to create a brand of scientifically engineered food products for direct distribution to pet owners across the globe.
A holistic approach to animal health
Our products leverage advances in human drug development to improve pet health and science. We are currently developing advanced medicines to help address several pet diseases, as well as scientifically engineered supplements and food designed to promote pet health.
Focusing on veterinary health
We’ve licensed 10 different patent-pending medications designed to treat high frequency pet killers such as leukemia, and many forms of brain and other tumors, as well as topical treatments for many inflammatory skin conditions. To complement our drug portfolio, we are also in the process of creating a proprietary line of organic pet food & supplements, which are on track to go to market in late 2020. The basis of these developments are from partnerships with leading human and pet health research institutions including Moleculin Biotech, CNS Pharmaceuticals, WPD Pharmaceuticals, and others. With a strong scientific advisory board, we are exploiting years of research targeting human health to exclusively focus on pet health.
For vets and pet owners
Animal Life Sciences was founded to bridge the gap between human and veterinary science, particularly in the field of cancer. Our cutting edge drug candidates are being engineered to go after very aggressive cancers, while our pet food line is being developed to boost pets immune systems to help fight against these ugly diseases and to help maximize their long-term health.
Re-framing human health & research for pets
Our business model mirrors that of human drug development and research. With our current funding, we will continue to develop our portfolio of technologies to bring them to the global market and we will continue to develop our proprietary line of healthy pet food and supplements to help generate revenue for us to scale our distribution.
Reaching 2 key markets
Animal Life Sciences capitalizes on two essential markets for pet owners. The first is medicine, which is valued at a market rate of $15.51B annually. The second is pet food, which is a $29.88B market. Over 68% of U.S. households own pets, and spend $70B+ annually on their pets.
Revolutionizing pet health research
Animal Life Sciences is utilizing cutting edge cancer research in humans to understand how best to address pet health issues. With our dual lines of medication and food, we occupy a unique position in the pet health industry and can provide an in depth understanding of pet health from a disease research perspective, as opposed to dietary research.
A new approach to pet disease prevention and treatment
Our ultimate goal is to help prevent and treat life-threatening diseases such as cancer in pets. Moving forward, we plan to use our scientific and clinical expertise to create a brand of scientifically engineered food products for direct distribution to pet owners across the globe. In addition to global distribution, we plan to finalize our drug development and to expand our development pipeline by licensing more drug technologies in the future.
Founded by leading scientist
DR. WALDEMAR PRIEBE: Department of Experimental Therapeutics, Division of Cancer Medicine
Dr. Priebe is a Professor of Medicinal Chemistry in the Department of Experimental Therapeutics at MD Anderson Cancer Center. He is the inventor of more than 50 patents, the author of more than 200 scientific publications, and discoverer of five drugs that have reached clinical studies in humans. As the founder or founding scientist of 6 pharmaceutical companies, including three listed on Nasdaq, Dr. Priebe has been integral in advancing multiple drugs through the preclinical pipeline and clinical development. Notably, Dr. Priebe was one of the founding scientists of Reata Pharmaceuticals, a $3 Billion Nasdaq listed company.